Altimmune, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 6, 2025 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the results of its IMPACT Phase 2b MASH trial, which failed to meet expectations [1][3]. Group 1: Class Action Details - The class action represents investors who purchased Altimmune securities between August 10, 2023, and June 25, 2025, with a deadline of October 6, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations and Trial Results - The complaint alleges that Altimmune's executives made overly positive statements while concealing material adverse facts about the trial results [3]. - On June 26, 2025, Altimmune announced that one of the primary endpoints in the trial did not achieve statistical significance, attributed to a higher-than-expected placebo response [4]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant single-day decline of 53.2% [5].